CY1112242T1 - Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης - Google Patents

Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης

Info

Publication number
CY1112242T1
CY1112242T1 CY20121100049T CY121100049T CY1112242T1 CY 1112242 T1 CY1112242 T1 CY 1112242T1 CY 20121100049 T CY20121100049 T CY 20121100049T CY 121100049 T CY121100049 T CY 121100049T CY 1112242 T1 CY1112242 T1 CY 1112242T1
Authority
CY
Cyprus
Prior art keywords
hydrogen
independently
alkyl
alkoxy
treatment
Prior art date
Application number
CY20121100049T
Other languages
Greek (el)
English (en)
Inventor
Jack Dejovin
Thomas M Rossi
Original Assignee
Galderma Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33457481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112242(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Pharma S.A. filed Critical Galderma Pharma S.A.
Publication of CY1112242T1 publication Critical patent/CY1112242T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CY20121100049T 2003-05-27 2012-01-17 Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης CY1112242T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47361103P 2003-05-27 2003-05-27
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
EP04753601.6A EP1631293B2 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea

Publications (1)

Publication Number Publication Date
CY1112242T1 true CY1112242T1 (el) 2015-12-09

Family

ID=33457481

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20121100049T CY1112242T1 (el) 2003-05-27 2012-01-17 Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
CY2014028C CY2014028I1 (el) 2003-05-27 2014-07-31 Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
CY20201100775T CY1123393T1 (el) 2003-05-27 2020-08-18 Ενωσεις, συνθεσεις και μεθοδοι για τη θεραπεια ή την προληψη της ροδοχρωμης ακμης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2014028C CY2014028I1 (el) 2003-05-27 2014-07-31 Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
CY20201100775T CY1123393T1 (el) 2003-05-27 2020-08-18 Ενωσεις, συνθεσεις και μεθοδοι για τη θεραπεια ή την προληψη της ροδοχρωμης ακμης

Country Status (22)

Country Link
US (13) US7439241B2 (US20050276830A1-20051215-C00018.png)
EP (3) EP2815748B1 (US20050276830A1-20051215-C00018.png)
CN (4) CN1829518B (US20050276830A1-20051215-C00018.png)
AT (1) ATE530185T1 (US20050276830A1-20051215-C00018.png)
AU (1) AU2004242967C1 (US20050276830A1-20051215-C00018.png)
CA (1) CA2530938C (US20050276830A1-20051215-C00018.png)
CY (3) CY1112242T1 (US20050276830A1-20051215-C00018.png)
DK (3) DK2815748T3 (US20050276830A1-20051215-C00018.png)
ES (3) ES2376172T5 (US20050276830A1-20051215-C00018.png)
HK (3) HK1084591A1 (US20050276830A1-20051215-C00018.png)
HR (1) HRP20150957T1 (US20050276830A1-20051215-C00018.png)
HU (3) HUE051833T2 (US20050276830A1-20051215-C00018.png)
IL (1) IL172612A (US20050276830A1-20051215-C00018.png)
LT (1) LT2815748T (US20050276830A1-20051215-C00018.png)
LU (1) LU92462I2 (US20050276830A1-20051215-C00018.png)
MX (1) MXPA05014107A (US20050276830A1-20051215-C00018.png)
NO (1) NO333468B1 (US20050276830A1-20051215-C00018.png)
NZ (1) NZ544300A (US20050276830A1-20051215-C00018.png)
PL (3) PL2815748T3 (US20050276830A1-20051215-C00018.png)
PT (3) PT2388007E (US20050276830A1-20051215-C00018.png)
SI (3) SI2388007T1 (US20050276830A1-20051215-C00018.png)
WO (1) WO2004105703A2 (US20050276830A1-20051215-C00018.png)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
MXPA06013649A (es) * 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US20080095735A1 (en) * 2005-01-31 2008-04-24 Kross Robert D Skin-Protective Polymer For Use In Teat Care Compositions
DE202005002183U1 (de) 2005-02-04 2005-04-14 Beiersdorf Ag Hautverwöhnende Cremelotion
CA2600384C (en) * 2005-03-30 2016-08-30 Revance Therapeutics, Inc. Compositions and methods for treating acne
CN101198362B (zh) 2005-06-17 2014-03-12 威斯康星校友研究基金会 在癌症化疗和放疗时保护细胞的局部血管收缩剂制品和方法
WO2007002447A2 (en) * 2005-06-23 2007-01-04 Bioform Medical, Inc. Compositions for treating rosacea
FR2894474B1 (fr) * 2005-12-12 2008-04-11 Galderma Res & Dev Gel depigmentant hydroalcoolique
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
WO2009017705A1 (en) 2007-07-27 2009-02-05 Galderma Laboratories L.P. Compounds, formulations, and methods for reducing skin wrinkles, creasing and sagging
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
EP2207424B1 (en) * 2007-11-16 2014-06-04 Allergan, Inc. Compositions and methods for treating purpura
BRPI0822095A2 (pt) * 2007-12-21 2014-10-07 Galderma Lab Inc Método para reduzir o sangramento e/ou hematoma em um paciente
IE20070935A1 (en) * 2007-12-21 2009-06-24 Trinity College Dublin Guanidine based compounds and their use in the treatment of mental and neurological disorders.
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
SI2320911T1 (sl) 2008-08-01 2014-12-31 Eye Therapies Llc Vazokonstrikcijski sestavki in metode uporabe
US20160184354A1 (en) * 2009-01-23 2016-06-30 Jr Chem, Llc Rosacea treatments and kits for performing them
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
CA2762107A1 (en) * 2009-05-15 2010-11-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
BRPI1011423A2 (pt) * 2009-05-29 2016-03-15 Galderma Res & Dev composição injetável, kit e método cosmético.
KR20120125230A (ko) * 2009-10-26 2012-11-14 갈더마파마 에스.아. 급성 홍반 치료 또는 예방 방법
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
WO2011117377A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
WO2011117378A2 (en) * 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
RU2587041C2 (ru) 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
CA2810746A1 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
EP2600832A1 (en) * 2010-08-06 2013-06-12 Galderma Research & Development Combination of compounds for treating or preventing skin diseases
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
AU2011317642A1 (en) * 2010-10-21 2013-05-02 Galderma S.A. Topical gel composition
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
JP2013540143A (ja) * 2010-10-21 2013-10-31 ガルデルマ・ソシエテ・アノニム ブリモニジンゲル組成物及び使用方法
EP3093017B1 (en) * 2010-11-16 2021-01-06 Allergan, Inc. Pharmaceutical composition comprising (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol for treating optic neuropathy
ES2843696T3 (es) * 2010-12-03 2021-07-20 Epi Health Llc Composiciones farmacéuticas en crema que comprenden oximetazolina para tratar la rosácea
JP2013545800A (ja) 2010-12-20 2013-12-26 コルゲート・パーモリブ・カンパニー 親水性活性剤、疎水性構造化剤および油担体を含有するゼラチンカプセル化された口腔ケア組成物
WO2012083397A1 (en) 2010-12-22 2012-06-28 Silvestre Labs Químia E Farmaceutica Ltda. Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
CN103458897A (zh) * 2011-02-15 2013-12-18 阿勒根公司 用于治疗红斑痤疮的症状的羟甲唑啉药物乳膏组合物
CN102260608B (zh) * 2011-06-23 2012-07-04 江苏安惠生物科技有限公司 灵芝肥皂及其制备方法
BR112014000876A2 (pt) * 2011-07-14 2017-02-21 Allergan Inc composições em gel de oximetazolina e métodos de uso
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
KR20140091543A (ko) 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
CA2850277A1 (en) 2011-10-19 2013-04-25 Galderma S.A. Method for treating capillary hemangiomas
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
RU2692245C2 (ru) 2011-12-11 2019-06-24 Рекро Фарма, Инк. Интраназальные композиции дексмедетомидина и способы их применения
CA2863760A1 (en) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
JP2016503051A (ja) * 2012-12-24 2016-02-01 ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド ナンセンス変異に起因する遺伝性疾患を治療する作用剤、及びこれを同定する方法
US9861645B2 (en) 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
CN105188691A (zh) 2013-05-06 2015-12-23 阿勒根公司 用于治疗组织创伤的α-肾上腺素能激动剂
EP3024462A2 (en) * 2013-07-26 2016-06-01 Galderma Research & Development Method for treating skin thickening
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
CA2951725C (en) 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
ES2671734T3 (es) 2014-06-30 2018-06-08 Galderma S.A. Procedimiento de tratamiento de los sofocos asociados con tumores carcinoides y síndrome carcinoide
RU2560698C1 (ru) * 2014-08-15 2015-08-20 Общество с ограниченной ответственностью "Уральский медико-химический центр" (ООО "УМХЦ") Средство наружной терапии больных акне
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
WO2017007910A1 (en) 2015-07-09 2017-01-12 Galderma S.A. Method of reducing hair loss associated with chemotherapy
FR3041537B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
WO2017085226A1 (en) * 2015-11-17 2017-05-26 Galderma Sa Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
US10617688B2 (en) 2016-03-22 2020-04-14 Doris Maria HEXSEL Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas
EP3476393A4 (en) * 2016-06-28 2019-07-17 Doris Maria Hexsel USE OF AN ACTIVE AGENT FOR THE TREATMENT OF TELANGIEKTATISCHEM MELASMA
CN109265448B (zh) * 2018-11-15 2020-09-15 三峡大学 一类含叔丁基的n-咪唑乙酰基二氢喹喔啉类衍生物，合成方法及其作为杀菌剂上的应用
US20200261402A1 (en) 2019-02-19 2020-08-20 Sol-Gel Technologies Ltd. Method for treatment of moderate to severe erythema symptoms in rosacea patients
MX2021012824A (es) 2019-05-01 2022-10-19 Clexio Biosciences Ltd Métodos para tratar el prurito.
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
EP4203958A1 (en) * 2020-08-26 2023-07-05 Oticara, Inc. Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation
RU2766973C1 (ru) * 2021-10-05 2022-03-16 Татьяна Сергеевна Русина Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа
WO2023130086A1 (en) * 2021-12-31 2023-07-06 Jss Research, Llc Compositions and methods for topical treatment of vascular conditions

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US3560501A (en) 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3594380A (en) 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
DE2924005C2 (de) * 1979-06-13 1984-07-05 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Isosorbiddinitrat enthaltendes Mittel
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5326763A (en) 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5198442A (en) 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5077292A (en) 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5237072A (en) 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
US5292517A (en) * 1992-02-25 1994-03-08 Allergan, Inc. pH sensitive, reversible gelling, copolymeric erodible drug delivery system
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
JP3683908B2 (ja) 1993-10-13 2005-08-17 アラーガン、インコーポレイテッド （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1996013267A2 (en) 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US5620416A (en) * 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US5753637A (en) 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
WO1998036730A2 (de) 1997-02-21 1998-08-27 Beiersdorf Ag Zubereitungen für die behandlung von rosacea
JP2001519815A (ja) * 1997-04-10 2001-10-23 エイジェニックス・インコーポレイテッド アレルゲン誘発性障害の治療におけるラクトフェリンの使用
JPH1129482A (ja) 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
US6513247B1 (en) * 1997-05-29 2003-02-04 Ariel Krasik-Geiger Calibrated angle and depth scissors
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
IN185228B (US20050276830A1-20051215-C00018.png) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
WO2000076502A1 (en) 1999-06-11 2000-12-21 The Ohio State University Research Foundation Methods and compositions for treating raynaud's phenomenon and scleroderma
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6147102A (en) 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
ES2223772T3 (es) * 2000-01-31 2005-03-01 Pfizer Products Inc. Pirimidincarboxamidas utiles como inhibidores de las isozimas pde4.
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
RU2311928C2 (ru) 2000-07-14 2007-12-10 Аллерган Инк. Композиции, содержащие альфа-2-адренергические агонисты
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP2004512369A (ja) 2000-10-30 2004-04-22 ユニバーシティ・オブ・チューリッヒ 尿失禁の治療のためのｇｎｒｈアナログ
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP1385496A4 (en) * 2001-05-09 2006-03-29 Univ Michigan USE OF COMPOSITIONS FOR THE TREATMENT OF ROSACEA
TNSN02063A1 (en) * 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
US7115724B2 (en) * 2001-08-22 2006-10-03 Wyeth Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor
US7704530B2 (en) * 2001-09-14 2010-04-27 Kenji Nakamura Antimicrobially treated material and methods of preventing coloring thereof
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040092482A1 (en) 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
WO2004103233A1 (en) 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
FR2862537B1 (fr) * 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation du fepradinol pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
MXPA06013649A (es) * 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
AU2007219040B2 (en) * 2006-02-20 2012-01-19 Commonwealth Scientific And Industrial Research Organisation Method and composition for priming wood and natural fibres
WO2008140781A1 (en) * 2007-05-09 2008-11-20 Atherogenics, Inc. Spiro compounds for treatment of inflammatory disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011117377A2 (en) * 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Also Published As

Publication number Publication date
US20130172359A1 (en) 2013-07-04
PT2815748T (pt) 2020-08-31
HRP20150957T1 (hr) 2015-11-20
US20100021402A1 (en) 2010-01-28
US20120277241A1 (en) 2012-11-01
PT1631293E (pt) 2012-02-01
ATE530185T1 (de) 2011-11-15
EP2815748B1 (en) 2020-08-05
EP1631293B1 (en) 2011-10-26
NO333468B1 (no) 2013-06-17
US20160220565A1 (en) 2016-08-04
NZ544300A (en) 2009-03-31
CN102743380B (zh) 2015-08-12
LU92462I2 (fr) 2015-11-02
EP2815748A1 (en) 2014-12-24
CN101380321B (zh) 2013-03-27
WO2004105703A3 (en) 2005-03-17
MXPA05014107A (es) 2006-03-17
CA2530938A1 (en) 2004-12-09
US20150202202A1 (en) 2015-07-23
US7439241B2 (en) 2008-10-21
US20060264515A1 (en) 2006-11-23
US20100227867A1 (en) 2010-09-09
DK2815748T3 (da) 2020-08-24
CY2014028I2 (el) 2015-12-09
ES2376172T5 (es) 2015-01-08
DK2388007T3 (en) 2015-09-28
SI2388007T1 (sl) 2016-01-29
CY1123393T1 (el) 2021-12-31
PL1631293T5 (pl) 2015-04-30
AU2004242967C1 (en) 2015-12-24
HK1164126A1 (en) 2012-09-21
CN101380321A (zh) 2009-03-11
SI1631293T1 (sl) 2012-02-29
CN101816793B (zh) 2012-08-15
EP1631293A4 (en) 2009-05-06
PT2388007E (pt) 2015-10-14
CN1829518B (zh) 2010-09-08
US8231885B2 (en) 2012-07-31
AU2004242967B2 (en) 2009-05-28
DK1631293T3 (da) 2012-02-13
HUE051833T2 (hu) 2021-03-29
DK1631293T4 (en) 2015-01-12
ES2547336T3 (es) 2015-10-05
CN101816793A (zh) 2010-09-01
SI2815748T1 (sl) 2020-11-30
US8557817B2 (en) 2013-10-15
LT2815748T (lt) 2020-11-25
HK1084591A1 (en) 2006-08-04
US20130172358A1 (en) 2013-07-04
IL172612A (en) 2013-03-24
US7838563B2 (en) 2010-11-23
US20040242588A1 (en) 2004-12-02
EP2388007A1 (en) 2011-11-23
EP1631293B2 (en) 2014-10-08
HUE027616T2 (en) 2016-11-28
WO2004105703A2 (en) 2004-12-09
HK1204996A1 (en) 2015-12-11
US20050276830A1 (en) 2005-12-15
PL2388007T4 (pl) 2016-03-31
CA2530938C (en) 2011-12-13
EP1631293A2 (en) 2006-03-08
EP2388007B1 (en) 2015-06-24
CY2014028I1 (el) 2015-12-09
PL1631293T3 (pl) 2012-03-30
AU2004242967A1 (en) 2004-12-09
US8426410B2 (en) 2013-04-23
ES2812532T3 (es) 2021-03-17
CN102743380A (zh) 2012-10-24
PL2815748T3 (pl) 2020-11-16
SI1631293T2 (sl) 2015-02-27
PL2388007T3 (pl) 2016-01-29
US8993571B2 (en) 2015-03-31
NO20056104L (no) 2006-02-03
US20100130502A1 (en) 2010-05-27
US8859551B2 (en) 2014-10-14
US20170216282A1 (en) 2017-08-03
CN1829518A (zh) 2006-09-06
ES2376172T3 (es) 2012-03-09
HUS1400029I1 (hu) 2017-10-30
US20060171974A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
CY1112242T1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
CY1105233T1 (el) Παραγωγα κατιοντος 1,2,4 - θειαδιαζολιου ως ρυθμιστες υποδοχεα μελανοκορτινης
BR0212983A (pt) Composto, uso do composto, e, intermediários de sìntese
DE69332563D1 (de) 1-(2-oxo-acetyl)-piperidin-2-carbonsäure derivate als sensibilisatoren für multi-drug-resistente krebszellen
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
DE69535805D1 (de) Neue Carbamate- und Harnstoffderivate als Mittel gegen Multidrugresistenz
BRPI0511519A (pt) método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
BRPI0415209A (pt) derivados de tetraidronaftaleno, processo para a produção deles e seu emprego como agentes antiinflamatórios
YU13699A (sh) Primena 1-hidroksi-2-piridona za dobijanje leka za lečenje infekcija kože
BR9812892A (pt) 2 4-diamino-1,3,5-triazinas substituìdas e seu emprego como herbicidas
AR029461A1 (es) Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento
IS6914A (is) 2-þíó-útskiptar imídasólafleiður og notkun þeirraí lyfjaiðnaðinum
NO975028L (no) Piperazinoderivater som neurokininantagonister
YU37597A (en) New pyranosid derivatives
BRPI0012329B8 (pt) derivados de benzofurano, processo para sua preparação e uso dos mesmos.
CY1114372T1 (el) Ενωσεις, τυποποιησεις και μεθοδοι για τη θεραπεια ή την προληψη φλεγμονωδων δερματικων παθησεων
BR0111074A (pt) N-hidroxiformamidas biciclil ou heterobiciclilme-tanossulfonilamino-substituìdos
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
BR0212860A (pt) Processo para preparação de derivados de piridil-alquilsulfonil pirazol
EA200500235A1 (ru) Новые производные пиперазинона для лечения нарушений, связанных с 5-ht-рецептором
UY26347A1 (es) Derivados de bencimidazol sustituidos con arilsulfonamida, procedimiento para su preparación y su empleo como medicamentos.